Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -14.87% is 42% above its 5-year average of -25.84%, around the middle of its 5-year range (-106.73%–63.14%).
26.06% above its 12-month average of -20.11%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.47%.
RETURN ON ASSETS (ROA)
-14.87%
RETURN ON ASSETS (ROA) AVG TTM
-20.11%
RETURN ON ASSETS (ROA) AVG 3Y
-27.86%
RETURN ON ASSETS (ROA) AVG 5Y
-25.84%
RETURN ON ASSETS (ROA) AVG 10Y
-42.94%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.06%
CURRENT VS 3Y AVG
+46.63%
CURRENT VS 5Y AVG
+42.45%
CURRENT VS 10Y AVG
+65.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+53.91%
vs the sector median at left
Ovid Therapeutics Inc.
Market Cap
$442.34M
Return on Assets (ROA)
-14.87%
TTM Avg
-20.11%
3Y Avg
-27.86%
5Y Avg
-25.84%
Market Cap
$439.55M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
Market Cap
$445.71M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$438.07M
Return on Assets (ROA)
-83.42%
TTM Avg
-53.06%
3Y Avg
-45.42%
5Y Avg
-42.54%
Market Cap
$435.61M
Return on Assets (ROA)
-29.57%
TTM Avg
-40.44%
3Y Avg
-13.88%
5Y Avg
-8.39%
Market Cap
$452.54M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
Market Cap
$431.97M
Return on Assets (ROA)
-19.71%
TTM Avg
-24.50%
3Y Avg
-30.22%
5Y Avg
-31.88%
Market Cap
$426.51M
Return on Assets (ROA)
-86.35%
TTM Avg
-25.00%
3Y Avg
-21.41%
5Y Avg
-20.43%
Market Cap
$424.10M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $442.34M | -14.87% | -20.11% | -27.86% | -25.84% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -0.01% | -18.05% | -43.07% | -43.70% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | -35.10% | -26.63% | -37.28% | -39.51% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | -83.42% | -53.06% | -45.42% | -42.54% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | -29.57% | -40.44% | -13.88% | -8.39% |
| NRC Health (NRC)vs › | $452.54M | 4.30% | 13.65% | 19.24% | 21.45% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -19.71% | -24.50% | -30.22% | -31.88% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -86.35% | -25.00% | -21.41% | -20.43% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -3.84% | -6.38% | -6.57% | -4.38% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | -36.19% | -33.16% | -60.79% | -52.41% |
ROA
-14.9%
ROE
-16.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -11.54% |
| 2024-12-31 | -28.68% |
| 2023-12-31 | -36.34% |
| 2022-12-31 | -34.89% |
| 2021-12-31 | 63.14% |
| 2020-12-31 | -106.73% |
| 2019-12-31 | -74.79% |
| 2018-12-31 | -109.09% |
| 2017-12-31 | -72.44% |
| 2016-12-31 | -42.27% |
| 2015-12-31 | -18.70% |
| 2014-12-31 | -9.20% |
